The rapid, massive growth of COVID-19 authors in the scientific literature
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
We examined the extent to which the scientific workforce in different fields was engaged in publishing COVID-19-related papers. According to Scopus (data cut, 1 August 2021), 210 183 COVID-19-related publications included 720 801 unique authors, of which 360 005 authors had published at least five full papers in their career and 23 520 authors were at the top 2% of their scientific subfield based on a career-long composite citation indicator. The growth of COVID-19 authors was far more rapid and massive compared with cohorts of authors historically publishing on H1N1, Zika, Ebola, HIV/AIDS and tuberculosis. All 174 scientific subfields had some specialists who had published on COVID-19. In 109 of the 174 subfields of science, at least one in 10 active, influential (top 2% composite citation indicator) authors in the subfield had authored something on COVID-19. Fifty-three hyper-prolific authors had already at least 60 (and up to 227) COVID-19 publications each. Among the 300 authors with the highest composite citation indicator for their COVID-19 publications, most common countries were USA ( n = 67), China ( n = 52), UK ( n = 32) and Italy ( n = 18). The rapid and massive involvement of the scientific workforce in COVID-19-related work is unprecedented and creates opportunities and challenges. There is evidence for hyper-prolific productivity.
Article activity feed
-
-
-
-
SciScore for 10.1101/2020.12.15.422900: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Certain limitations should be discussed. First, current Scopus data have high precision and recall (98.1% and 94.4%, respectively),1 but some authors may be split in two or more records and some ID records may include papers from …
SciScore for 10.1101/2020.12.15.422900: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Institutional Review Board Statement not detected. Randomization not detected. Blinding not detected. Power Analysis not detected. Sex as a biological variable not detected. Table 2: Resources
No key resources detected.
Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:Certain limitations should be discussed. First, current Scopus data have high precision and recall (98.1% and 94.4%, respectively),1 but some authors may be split in two or more records and some ID records may include papers from two or more authors. These errors may affect single authors but are unlikely to affect the overall picture obtained in these analyses. Second, field and subfield classification follows a well-known established method, though published items are not precisely categorizable in scientific fields. Third, data on citation impact of COVID-19 authors are too early to appraise with confidence, and the ranking of specific scientists is highly tenuous and can quickly change with relatively small changes in citation counts. The bigger picture of author characteristics rather than specific names should be the focus of these data. Fourth, since many COVID-19 accepted papers and preprints are not yet indexed in Scopus, fields with slower publication and indexing may be relatively under-represented in the analyses. As the pandemic matures, the science of COVID-19 should also mature. Important remaining questions can be raised about the extent and duration of this “covidization” of research. Will scientists continue to flock from different disciplines into COVID-19 research? What consequences might this have for other areas of important investigation – could non-COVID-19 topics be unfairly neglected? Is the response proportional to the magnitude of the crisis? What ...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
-